Theratechnologies (THTX) Competitors $3.13 +0.77 (+32.63%) Closing price 07/3/2025 03:59 PM EasternExtended Trading$3.16 +0.02 (+0.80%) As of 07/3/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock THTX vs. ATYR, MREO, CGEM, AMLX, ZYBT, ORKA, SIGA, CMPS, PGEN, and TRMLShould you be buying Theratechnologies stock or one of its competitors? The main competitors of Theratechnologies include aTyr Pharma (ATYR), Mereo BioPharma Group (MREO), Cullinan Therapeutics (CGEM), Amylyx Pharmaceuticals (AMLX), Zhengye Biotechnology (ZYBT), Oruka Therapeutics (ORKA), Siga Technologies (SIGA), COMPASS Pathways (CMPS), Precigen (PGEN), and Tourmaline Bio (TRML). These companies are all part of the "pharmaceutical products" industry. Theratechnologies vs. Its Competitors aTyr Pharma Mereo BioPharma Group Cullinan Therapeutics Amylyx Pharmaceuticals Zhengye Biotechnology Oruka Therapeutics Siga Technologies COMPASS Pathways Precigen Tourmaline Bio Theratechnologies (NASDAQ:THTX) and aTyr Pharma (NASDAQ:ATYR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability. Which has stronger earnings & valuation, THTX or ATYR? Theratechnologies has higher revenue and earnings than aTyr Pharma. Theratechnologies is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTheratechnologies$85.87M1.68-$8.31M-$0.08-39.13aTyr Pharma$230K2,033.07-$64.02M-$0.81-6.49 Is THTX or ATYR more profitable? aTyr Pharma has a net margin of 0.00% compared to Theratechnologies' net margin of -4.18%. Theratechnologies' return on equity of 0.00% beat aTyr Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Theratechnologies-4.18% N/A -0.37% aTyr Pharma N/A -87.09%-64.77% Does the media refer more to THTX or ATYR? In the previous week, Theratechnologies had 7 more articles in the media than aTyr Pharma. MarketBeat recorded 11 mentions for Theratechnologies and 4 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.66 beat Theratechnologies' score of 0.13 indicating that aTyr Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theratechnologies 1 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral aTyr Pharma 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer THTX or ATYR? aTyr Pharma has a consensus target price of $20.20, suggesting a potential upside of 284.47%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts plainly believe aTyr Pharma is more favorable than Theratechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Theratechnologies 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00aTyr Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Which has more risk & volatility, THTX or ATYR? Theratechnologies has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Do institutionals and insiders have more ownership in THTX or ATYR? 61.7% of aTyr Pharma shares are owned by institutional investors. 3.7% of aTyr Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryaTyr Pharma beats Theratechnologies on 10 of the 16 factors compared between the two stocks. Get Theratechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for THTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding THTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart THTX vs. The Competition Export to ExcelMetricTheratechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$147.14M$2.91B$5.54B$9.05BDividend YieldN/A2.44%5.24%4.02%P/E Ratio-39.1321.5627.4320.22Price / Sales1.68281.76416.87118.64Price / CashN/A42.7336.8958.07Price / Book-5.697.518.035.67Net Income-$8.31M-$55.05M$3.18B$249.13M7 Day Performance33.19%4.61%2.88%3.28%1 Month Performance19.01%4.72%3.69%5.56%1 Year Performance120.42%5.92%36.02%21.12% Theratechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)THTXTheratechnologiesN/A$3.13+32.6%N/A+131.9%$147.14M$85.87M-39.13140News CoverageUpcoming EarningsAnalyst DowngradeGap UpHigh Trading VolumeATYRaTyr Pharma2.8029 of 5 stars$4.98-4.6%$20.20+305.6%N/A$464.60M$230K-6.1553High Trading VolumeMREOMereo BioPharma Group1.9754 of 5 stars$2.74-3.9%$7.60+177.4%-19.9%$453.15M$10M-39.1440CGEMCullinan Therapeutics1.5334 of 5 stars$7.58-1.2%$30.00+295.8%-53.5%$452.64MN/A-2.6030AMLXAmylyx Pharmaceuticals3.5169 of 5 stars$5.02-0.6%$10.14+102.0%+255.9%$450.16M$87.37M-1.61200ZYBTZhengye BiotechnologyN/A$7.43-20.1%N/AN/A$438.65MN/A0.00278News CoverageLockup ExpirationORKAOruka Therapeutics2.2099 of 5 stars$10.90-6.7%$40.38+270.4%N/A$437.30MN/A-2.42N/ANews CoverageSIGASiga Technologies0.9144 of 5 stars$6.19+1.1%N/A-13.0%$437.22M$138.72M9.2440CMPSCOMPASS Pathways1.652 of 5 stars$2.35-49.2%$17.00+623.4%-48.0%$433.19MN/A-1.18120Gap DownHigh Trading VolumePGENPrecigen3.7179 of 5 stars$1.48+2.1%$6.00+305.4%+10.5%$428.01M$3.92M-2.64190News CoverageTRMLTourmaline Bio2.1424 of 5 stars$17.02+2.3%$49.33+189.9%+30.7%$427.41MN/A-5.3044 Related Companies and Tools Related Companies ATYR Competitors MREO Competitors CGEM Competitors AMLX Competitors ZYBT Competitors ORKA Competitors SIGA Competitors CMPS Competitors PGEN Competitors TRML Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:THTX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theratechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theratechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
